Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Regaining Physical Fitness in A Post-Pandemic World
By Sheri Colberg, PhD
Letter from the Editor
I have decided that the pandemic and the isolation associated with it has had polar effects on fitness. Some people like myself have not had to travel and my riding mileage has increased, while others could not go to the gym or even walk around the block.
To help you make the best of your time and work your way back to fitness, Dr. Colberg has prepared a special feature.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: FDA Removes Canagliflozin Boxed Warning
See this week’s Fact.
TOP STORIES — Diabetes News and Research
By Sheri Colberg, PhD
Yes, I know we’re still dealing with a life-changing pandemic around the world and especially in most areas of the United States, but it is still worth thinking ahead to what comes next. Despite our discussion last month on non-gym fitness trends, it is more than likely that many of us have experienced a change (most often a decrease) in our daily physical activities and, subsequently, in our aerobic and muscular fitness levels.
Could a primarily plant-based high protein diet be the secret to longevity?
A promising new study paves the way for a new pharmacologic treatment to regenerate beta cells in patients with diabetes.
Fact: FDA Removes Boxed Warning for Amputation Risk from Canagliflozin
The FDA has removed the boxed warning concerning amputation risk from the diabetes drug canagliflozin (Invokana, Invokamet, Invokamet XR). The removal of the boxed warning was based on the FDA’s review of new data from 3 clinical trials. The agency’s requirement of the boxed warning in 2017 was based on its assessment that the risk of amputations was substantial compared with the potential benefit of canagliflozin. More recent clinical trials have shown significant benefits to the heart and kidneys. In 2018, canagliflozin was approved by the FDA for its potential to reduce the risk of major heart-related events, including heart attack, stroke, or deaths in patients with T2D who also have identified heart disease. In 2019, canagliflozin was approved to reduce the risk of end-stage kidney disease, worsening kidney function, heart-related death, and hospitalization due to heart failure in some patients with T2D and diabetic kidney disease. Because the risk of amputation remains elevated with the use of canagliflozin, it is described in the warning and precautions section of the drug’s prescribing information. MedWatch Safety Alert – Boxed Warning about Risk of Leg and Foot Amputations Removed | druginfo@fda.hhs.gov
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Fairuz Afram, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences
Leyany Feijoo Ramos, PharmD. Candidate, LECOM School of Pharmacy
Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine – L|E|C|O|M School of Pharmacy
Jessica Rogers, PharmD candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Peter Jay Won, Pharm.D. Candidate, University of South Florida, Taneja College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com